- Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
-
Jun YK, Yoon H, Koh SJ, Kim AH, Kim KW, Park JW, Lee HJ, Kang HW, Im JP, Park YS, Kim JS, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN)
- KMID: 2541897
- Intest Res.
- 2023 Apr;21(2):244-251.
- doi: 10.5217/ir.2022.00057
Background/Aims: Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Rebound Phenomenon after Cessation of Cyclosporine for Guselkumab Therapy in Psoriasis
-
Park SH, Jung SY
- KMID: 2538565
- Korean J Dermatol.
- 2022 Dec;60(10):679-682.
Cyclosporine is one of the main therapeutic agents for psoriasis. It is known that psoriasis relapses 2∼3 months after discontinuation of cyclosporine, and exacerbation due to abrupt discontinuation of cyclosporine... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Generalized Granuloma Annulare Development in a Psoriasis Patient Treated with Interleukin-12/23 Blockers
-
Kim J, Jang B, Kim Y, Won SH, Bae KN, Lee J, Shin K, Kim H, Ko H, Kim MB, Kim B
- KMID: 2536322
- Korean J Dermatol.
- 2022 Nov;60(9):606-610.
Granuloma annulare is a relatively common inflammatory skin disease. The etiology is unknown; however, drugs have been considered as one of the predisposing conditions, and a few cases of granuloma... -
- CITED
-
- Close
- SHARE
-
- Close
- Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis
-
Oh S, Choi S, Yoon HS
- KMID: 2533604
- Ann Dermatol.
- 2022 Oct;34(5):321-330.
- doi: 10.5021/ad.22.003
Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics... -
- CITED
-
- Close
- SHARE
-
- Close
- Brazilian Berry Extract Differentially Induces Inflammatory and Immune Responses in Androgen Dependent and Independent Prostate Cancer Cells
-
Kido LA, Urra Rossetto IM, Baseggio AM, Chiarotto GB, Alves LF, Santos FR, Almeida Lamas Cd, Maróstica Jr MR, Alves Cagnon VH
- KMID: 2533967
- J Cancer Prev.
- 2022 Sep;27(3):182-191.
- doi: 10.15430/JCP.2022.27.3.182
Jaboticaba is a Brazilian berry, which is rich in fibers and bioactive compounds and shows high antioxidant and antiproliferative activities. Prostate cancer (PCa) is the second most common type of... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
-
Na SY, Kim YS
- KMID: 2533133
- Korean J Intern Med.
- 2022 Sep;37(5):906-919.
- doi: 10.3904/kjim.2022.152
The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic effect of multiple functional minicircle vector encoding anti-CD25/IL-10/CXCR3 in allograft rejection model
-
Lim SW, Shin YJ, Cui S, Ko EJ, Yoo SH, Chung BH, Yang CW
- KMID: 2533146
- Korean J Intern Med.
- 2022 Sep;37(5):1031-1049.
- doi: 10.3904/kjim.2021.299
Background/Aims: We previously proposed minicircle vector technology as the potential platform for the development and production of new biologics. In this study, we have designed a novel target molecule for... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of the Switching Patterns of Biologics and Their Efficacy after Switching in Moderate-to-Severe Psoriasis Patients
-
Lee SM, Ko BC, Ahn SW, Uh JA, Seol JE, Kim H, Lee SK, Kim MS, Lee UH, Park SH, Jung SY, Park HJ
- KMID: 2532844
- Korean J Dermatol.
- 2022 Aug;60(7):420-428.
Background: Biologics-experienced patients are more likely to show a lower response to biologics than that of biologic-naïve patients. However, no consensus on switching biologics exists. Objective: We aimed to investigate the... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Risankizumab for the Treatment of Moderate to Severe Psoriasis in Korea: A Real-Life Experience
-
Ko BC, Lee SM, Park HJ
- KMID: 2531075
- Korean J Dermatol.
- 2022 Jun;60(5):307-315.
Background: Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to the p19 subunit of interleukin-23. Risankizumab has demonstrated rapid and excellent therapeutic effects in several clinical trials.... -
- CITED
-
- Close
- SHARE
-
- Close
- Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis
-
Choi S, Oh S, Yoon HS
- KMID: 2529978
- Ann Dermatol.
- 2022 Jun;34(3):173-181.
- doi: 10.5021/ad.2022.34.3.173
Background: With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved healthrelated quality of life as compared to... -
- CITED
-
- Close
- SHARE
-
- Close
- The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma
-
Kim SH, Lee H, Park SY, Park SY, Song WJ, Kim JH, Park HW, Cho YS, Yoon HJ, on behalf of the KoSAR investigators
- KMID: 2527288
- Korean J Intern Med.
- 2022 Feb;37(2):249-260.
- doi: 10.3904/kjim.2021.403
Severe asthma constitutes a serious health burden with significant morbidity and socioeconomic costs. The development and introduction of new biologics targeting type 2 inflammation changed the paradigm for management of... -
- CITED
-
- Close
- SHARE
-
- Close
- Sec-O-glucosylhamaudol mitigates inflammatory processes and autophagy via p38/JNK MAPK signaling in a rat neuropathic pain model
-
Oh SH, Kim SW, Kim DJ, Kim SH, Lim KJ, Lee K, Jung KT
- KMID: 2520748
- Korean J Pain.
- 2021 Oct;34(4):405-416.
- doi: 10.3344/kjp.2021.34.4.405
Background: This study investigated the effect of intrathecal Sec-O-glucosylhamaudol (SOG) on the p38/c-Jun N-terminal kinase (JNK) signaling pathways, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-related inflammatory responses, and autophagy... -
- CITED
-
- Close
- SHARE
-
- Close
- KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities
-
Kim J, Koh JH, Choi SJ, Jeon CH, Kwok SK, Kim SK, Choi CB, Lee J, Lee C, Nam EJ, Park YB, Lee SS, Kim TH, Park SH, Choe JY, Koh EM, Yoo DH, Song YW, Kim HA, Shin K
- KMID: 2520430
- J Rheum Dis.
- 2021 Oct;28(4):176-182.
- doi: 10.4078/jrd.2021.28.4.176
The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry is a nationwide observational cohort that captures detailed data on exposure of patients to biologic and targeted synthetic disease-modifying... -
- CITED
-
- Close
- SHARE
-
- Close
- Paradigm Shift of Pharmacovigilance: 10 Years’ Experience of Active Surveillance by One Regional Pharmacovigilance Center
-
Lee MG
- KMID: 2534667
- .
- 2021 Sep;13(2):87-90.
- doi: 10.56142/2021.13.2.87
21st century pharmacovigilance is not merely about the identification of adverse events but also includes systemic preand post-market surveillance and a complete understanding of the risks associated with certain drugs.... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Analysis of Treatment Outcomes Following Regular vs. Irregular Administration of Biologics in Patients with Psoriasis
-
Choi GW, Lim NJ, Shin JU, Lee HJ, Yoon MS, Kim DH
- KMID: 2518986
- Korean J Dermatol.
- 2021 Jul;59(6):440-446.
Background: Patients with stable psoriasis showing clear/near-clear response can consider extending the dosing interval of biologics. However, few studies have reported the treatment outcomes following irregular dosing intervals of biologics... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologic therapies for the treatment of psoriatic arthritis
-
Kim TJ
- KMID: 2513067
- J Korean Med Assoc.
- 2021 Feb;64(2):124-129.
- doi: 10.5124/jkma.2021.64.2.124
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease commonly associated with plaque psoriasis that, manifests with peripheral arthritis, dactylitis, enthesitis, and axial involvement. PsA can be progressive and harmful,... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologic therapies for the treatment of ankylosing spondylitis
-
Ahn SM, Kim YG
- KMID: 2513066
- J Korean Med Assoc.
- 2021 Feb;64(2):116-123.
- doi: 10.5124/jkma.2021.64.2.116
Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the axial skeleton. AS treatment aims to reduce pain and inflammation and maintain functional capacity. Nonsteroidal anti-inflammatory drugs are the... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologic therapies for the treatment of systemic lupus erythematosus
-
Park SH
- KMID: 2513065
- J Korean Med Assoc.
- 2021 Feb;64(2):109-115.
- doi: 10.5124/jkma.2021.64.2.109
Systemic lupus erythematosus is a typical autoimmune disease with a complex etiology, including the interaction of genetic/epigenetic factors and environmental and hormonal factors with innate immune cells or B/T lymphocytes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Biologic therapies for the treatment of rheumatoid arthritis
-
Choi SJ
- KMID: 2513063
- J Korean Med Assoc.
- 2021 Feb;64(2):95-104.
- doi: 10.5124/jkma.2021.64.2.95
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the synovial joints. If left untreated, persistent synovial inflammation can lead to cartilage and bone destruction, ultimately causing significant... -
- CITED
-
- Close
- SHARE
-
- Close
- Advantages and disadvantages of targeted therapy in patients with rheumatoid arthritis
-
Sung YK
- KMID: 2513062
- J Korean Med Assoc.
- 2021 Feb;64(2):90-93.
- doi: 10.5124/jkma.2021.64.2.90
With the recent understanding of the pathogenesis of rheumatoid arthritis at the cellular and molecular levels, as well as the rapid progress of biotechnology, targeted therapies have been developed and... -
- CITED
-
- Close
- SHARE
-
- Close
